February 19, 2015—In another sign of orphan drugs' rising prominence in drugmakers' portfolios, an industry blog reports that the Food and Drug Administration approved 53 percent more orphan products in 2014 than in 2013. … [Read more...]
More Details Emerge on 340B Audit of Drug Manufacturer
Fairness of allocation procedures also being examinedFebruary 12, 2015—More information about the first 340B program audit of a drug manufacturer emerged today during a drug industry government pricing conference in Washington. … [Read more...]
Hospitals Back HHS in 340B Orphan Drug Lawsuit
Groups file briefs defending HRSA's interpretive ruleFebruary 11, 2015—Hospital groups have asked a federal district judge to dismiss the drug industry's lawsuit challenging the 340B orphan drug exclusion interpretive rule. … [Read more...]
340B Omnibus Guidance Slated for June Release
Regulations coming on manufacturer penalties, ceiling prices, and dispute resolutionFebruary 5, 2015—The Health Resources and Services Administration plans in June to issue wide-ranging 340B program guidance on patient definition and other issues over which it lacks clear authority to regulate, the head of HRSA's Office of Pharmacy Affairs said today. … [Read more...]
HRSA Names Drugmakers Not Following 340B Orphan Drug Rule
Says purpose is to enable states to collect Medicaid rebatesFebruary 5, 2015—The Health Resources and Services Administration today identified 13 drug companies that are not complying with its 340B orphan drug exclusion interpretive rule. … [Read more...]
President Seeks $24.73 Million for 340B Oversight and Operations
Patient definition and hospital eligibility guidance "to be finalized" in fiscal year 2016February 2, 2015—The Obama administration is seeking $24.73 million to run the 340B drug discount program in the fiscal year that begins in October – more than double this year's funding level. The request came in the proposed fiscal year 2016 budget that the President sent to Congress today. … [Read more...]
Celgene Posts Notice on 340B Program Website
Explains why it stopped adding 340B and other providers to limited distribution networksJanuary 30, 2015—The biotech company Celgene, acting at the request of the Health Resources and Services Administration, has posted a notice on the 340B program website explaining why it has stopped adding providers to its limited distribution networks for three of its products, including its top-selling blood cancer drug Revlimid. … [Read more...]